Chiou WY, et al. - In this population-based matched cohort study, the researchers intended to examine the effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPSV23) in elderly patients who survived cancer for at least 5 years after initial cancer diagnosis. This study draws on data from the National Health Insurance Research Database (NHIRD) and released for research purposes by the National Health Research Institutes (NHRI), Taiwan. Among the thirty thousand, two hundred forty-nine patients with cancer, six thousand, seven hundred eighty-four patients were 75 years or older eligible for PPSV23 vaccination. In long-term cancer survivors, PPSV23 vaccination was linked with a significantly reduced rate of pneumonia hospitalisation.